pyrazines has been researched along with Sclerosis, Systemic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Channick, R; Chin, K; Coghlan, G; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Seibold, JR; Wigley, FM | 1 |
| Denton, CP; Frenoux, JM; Frey, A; Hachulla, É; Herrick, AL; Le Brun, FO; Riemekasten, G; Schwarting, A | 1 |
| Denton, CP; Herrick, AL | 1 |
| Domsic, RT; Pauling, JD; Saketkoo, LA | 1 |
| Brizzolara, R; Corallo, C; Cutolo, M; Giordano, N; Montagna, P; Paolino, S; Parodi, A; Pizzorni, C; Ruaro, B; Scabini, S; Smith, V; Soldano, S; Stratta, E; Sulli, A; Tavilla, PP; Trombetta, AC | 1 |
| Abedi, M; Ames, E; Blazar, BR; Chen, M; Grossenbacher, SK; Jagdeo, J; Mirsoian, A; Murphy, WJ; Pai, CC; Sun, K; Tellez, J | 1 |
| Allanore, Y; Bruni, C; Distler, O; Gabrielli, A; Iannone, F; Matucci-Cerinic, M; Praino, E | 1 |
| Budinger, GR; Chandel, NS; Chiarella, SE; Ghosh, AK; Go, LH; Jain, M; Kamp, DW; Lam, AP; Mutlu, GM; Pardo, A; Rivera, S; Selman, M; Sznajder, JI; Urich, D; Varga, J; Wu, M; Zirk, A | 1 |
| Chizzolini, C; Dayer, JM; Fineschi, S; Guerne, PA; Reith, W | 1 |
| Argiroffo, CB; Bongiovanni, M; Chizzolini, C; Dayer, JM; Djaafar, S; Donati, Y; Ferrari-Lacraz, S; Fineschi, S; Goffin, L; Naso, F; Pache, JC | 1 |
1 review(s) available for pyrazines and Sclerosis, Systemic
| Article | Year |
|---|---|
Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Topics: Abatacept; Acetamides; Antibodies, Monoclonal, Humanized; Biological Products; Clinical Trials as Topic; Fibrinolytic Agents; Fibrosis; Humans; Hypertension, Pulmonary; Indoles; Inflammation; Joints; Lisuride; Lung; PubMed; Pyrazines; Pyrazoles; Pyrimidines; Scleroderma, Systemic; Skin | 2017 |
3 trial(s) available for pyrazines and Sclerosis, Systemic
| Article | Year |
|---|---|
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Disease Progression; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Outcome Assessment, Health Care; Pyrazines; Risk Assessment; Scleroderma, Systemic; Survival Analysis | 2017 |
Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
Topics: Acetamides; Adult; Antihypertensive Agents; Bayes Theorem; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Treatment Outcome | 2017 |
Treatment of chronic graft-versus-host disease with bortezomib.
Topics: Animals; Boronic Acids; Bortezomib; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrazines; Scleroderma, Systemic; Skin; Transplantation, Homologous; Treatment Outcome; Tumor Cells, Cultured | 2014 |
7 other study(ies) available for pyrazines and Sclerosis, Systemic
| Article | Year |
|---|---|
Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic; Sugars | 2017 |
Reply.
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic | 2018 |
Patient Perceptions of the Raynaud's Condition Score Diary Provide Insight Into Its Performance in Clinical Trials of Raynaud's Phenomenon: Comment on the Article by Denton et al.
Topics: Acetamides; Adult; Humans; Pyrazines; Raynaud Disease; Scleroderma, Systemic | 2018 |
Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
Topics: Acetamides; Acetates; Actins; Aged; Cells, Cultured; Female; Fibroblasts; Gene Expression; Humans; Middle Aged; Muscle, Smooth; Myofibroblasts; Pyrazines; S100 Calcium-Binding Protein A4; Scleroderma, Systemic; Skin | 2018 |
Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.
Topics: Animals; Autocrine Communication; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fibroblasts; Fibrosis; Gene Expression Regulation; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; PPAR gamma; Proteasome Inhibitors; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta1 | 2012 |
Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts.
Topics: Acetylcysteine; Anthracenes; Boronic Acids; Bortezomib; Collagen Type I; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Matrix; Fibroblasts; Fibrosis; Genes, jun; Humans; JNK Mitogen-Activated Protein Kinases; Leupeptins; Matrix Metalloproteinase 1; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-jun; Pyrazines; RNA Polymerase II; RNA, Messenger; Scleroderma, Systemic; Skin; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Up-Regulation | 2006 |
In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.
Topics: Animals; Bleomycin; Boronic Acids; Bortezomib; Cells, Cultured; Collagen Type I; Fibrosis; Hydroxyproline; Leupeptins; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Proteasome Inhibitors; Protein Serine-Threonine Kinases; Pulmonary Fibrosis; Pyrazines; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta | 2008 |